GALT - Galectin Therapeutics Inc. News

Discover

GALT

Galectin Therapeutics Inc.

4.33

2 x 3.24

2 x 5.51

bid

ask

0.31

6.68%

2 @ 07:00 AM

4.33 +0.00 (0.00%)

Ytd	4.09%
1y	95.05%

4.28

day range

4.61

2.03

52 week range

7.13

Open	4.57	Prev Close	4.64	Low	4.28	High	4.61	Mkt Cap	285.16M
Vol	646.55K	Avg Vol	578.37K	EPS	-0.41	P/E	N/A	Forward P/E	-0.53
Beta	0.63	Short Ratio	42.37	Inst. Own	15.77%	Dividend	N/A	Div Yield	N/A
Ex Div Date	N/A	Earning	08-15	50-d Avg	2.67	200-d Avg	3.71	1yr Est	11.00

GALT News

benzinga.com

Top 3 Health Care Stocks That May Keep You Up At Night In June

Health care stocks flashing warning to momentum investors. RSI indicator shows overbought for DFTX,

benzinga.com

12 Health Care Stocks Moving In Tuesday's Intraday Session

Gainers Aditxt (NASDAQ:ADTX) shares increased by 151.6% to $0.05 during Tuesday's regular sessi

benzinga.com

HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target

HC Wainwright & Co. analyst Matthew Keller reiterates Galectin Therapeutics (NASDAQ:GALT) wit

benzinga.com

Galectin Therapeutics Announces Positive Feedback From Recent In Person Type C Meeting With FDA For

Galectin Therapeutics Inc. (NASDAQ: GALT), a biotechnology company focused on developing therapies f

benzinga.com

12 Health Care Stocks Moving In Friday's After-Market Session

benzinga.com

Galectin Therapeutics Q1 EPS $(0.08) Misses $(0.06) Estimate

Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.08) per share which missed the

benzinga.com

Galectin Therapeutics Announces Publication Of Results From NAVIGATE Phase 2b Clinical Trial Evaluat

Galectin Therapeutics Inc. (NASDAQ:GALT), a clinical-stage biotechnology company developing therapeu

benzinga.com

12 Health Care Stocks Moving In Tuesday's After-Market Session

benzinga.com

Galectin Therapeutics Q4 EPS $(0.08) Beats $(0.11) Estimate

Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.08) per share which beat the an

benzinga.com

Galectin Therapeutics To Host Virtual KOL Event On March 10, Focusing On Unmet Need And Current Trea

Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics

benzinga.com

12 Health Care Stocks Moving In Friday's Intraday Session

benzinga.com

HC Wainwright & Co. Maintains Buy on Galectin Therapeutics, Raises Price Target to $11

HC Wainwright & Co. analyst Matthew Keller maintains Galectin Therapeutics (NASDAQ:GALT) with

benzinga.com

12 Health Care Stocks Moving In Monday's After-Market Session

benzinga.com

12 Health Care Stocks Moving In Wednesday's After-Market Session

benzinga.com

Stitch Fix Posts Q4 Results, Joins Transocean, MBX Biosciences And Other Big Stocks Moving Lower In

U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Thursday.

benzinga.com

12 Health Care Stocks Moving In Monday's After-Market Session

benzinga.com

HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $6 Price Target

HC Wainwright & Co. analyst Matthew Keller reiterates Galectin Therapeutics (NASDAQ:GALT) wit

benzinga.com

Galectin Therapeutics Q2 EPS $(0.12) Beats $(0.16) Estimate

Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.12) per share which beat the an

benzinga.com

12 Health Care Stocks Moving In Friday's After-Market Session

benzinga.com

12 Health Care Stocks Moving In Friday's Intraday Session

benzinga.com

12 Health Care Stocks Moving In Wednesday's Intraday Session

benzinga.com

12 Health Care Stocks Moving In Tuesday's Intraday Session

benzinga.com

HC Wainwright & Co. Assumes Galectin Therapeutics at Buy, Announces Price Target of $6

HC Wainwright & Co. analyst Joseph Pantginis assumes Galectin Therapeutics (NASDAQ:GALT) with

benzinga.com

Galectin Therapeutics Q1 EPS $(0.15) Beats $(0.20) Estimate

Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.15) per share which beat the an

benzinga.com

Galectin Therapeutics Issues Presentation Highlighting Its Focused Pipeline, MASH Cirrhosis And Onco

https://docs.publicnow.com/viewDoc?hash_primary=6F7EA1F91A74272903B9A6CE2CA3BF2D89B3FA18

benzinga.com

HC Wainwright & Co. Reiterates Neutral on Galectin Therapeuticsto Neutral

HC Wainwright & Co. analyst Ed Arce reiterates Galectin Therapeutics (NASDAQ:GALT) from Neutr

benzinga.com

12 Health Care Stocks Moving In Friday's Pre-Market Session

benzinga.com

Dow Surges Over 600 Points, Gold Jumps 1.5%

benzinga.com

Nasdaq Jumps Over 300 Points, Novo Nordisk Shares Spike Higher

benzinga.com

Dow Surges 100 Points, Carnival Earnings Top Views

benzinga.com

Why Is Small Cap Galectin Therapeutics Stock Trading Lower On Friday?

Galectin Therapeutics' NAVIGATE trial shows belapectin reduces varices in MASH cirrhosis, but fa

benzinga.com

Galectin Therapeutics Presents 3 Abstracts At The American Association For The Study Of Liver Diseas

Patient population for the NAVIGATE trial is based on non-invasive tests and clinical criteria utili

benzinga.com

HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target

HC Wainwright & Co. analyst Ed Arce reiterates Galectin Therapeutics (NASDAQ:GALT) with a Buy

benzinga.com

Galectin Therapeutics Q3 2024 GAAP EPS $(0.18) Misses $(0.12) Estimate

Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.18) per share which missed the

benzinga.com

HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target

HC Wainwright & Co. analyst Ed Arce reiterates Galectin Therapeutics (NASDAQ:GALT) with a Buy

benzinga.com

Galectin Therapeutics Q2 EPS $(0.20) Misses $(0.16) Estimate

Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.20) per share which missed the

benzinga.com

Galectin Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying

benzinga.com

Galectin Therapeutics And 2 Other Penny Stocks Insiders Are Buying

benzinga.com

HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target

HC Wainwright & Co. analyst Ed Arce reiterates Galectin Therapeutics (NASDAQ:GALT) with a Buy

benzinga.com

Galectin Therapeutics Highlights Outcome Of Fifth Data and Safety Monitoring Board Meeting for NAVIG

Data and Safety Monitoring Board (DSMB) recommends the continuation, without modifications, of the a

benzinga.com

12 Health Care Stocks Moving In Friday's Intraday Session

benzinga.com

HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target

HC Wainwright & Co. analyst Ed Arce reiterates Galectin Therapeutics (NASDAQ:GALT) with a Buy

benzinga.com

Galectin Therapeutics: Q3 Earnings Insights

benzinga.com

Galectin Therapeutics Q3 EPS $(0.24) Misses $(0.16) Estimate;

Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.24) per share which missed the

benzinga.com

Galectin Therapeutics Reports The Outcome Of The Fourth Data And Safety Monitoring Board Meeting For

Galectin Therapeutics, Inc.

benzinga.com

Galectin Therapeutics To Present Update On Its Belapectin Liver Cirrhosis Program At The 20th Editio

Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galecti

benzinga.com

HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target

HC Wainwright & Co. analyst Ed Arce reiterates Galectin Therapeutics (NASDAQ:GALT) with a Buy

benzinga.com

Galectin Therapeutics Q2 EPS $(0.15) Beats $(0.21) Estimate

Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.15) per share which beat the an

benzinga.com

Galectin Therapeutics And 3 Other Stocks Under $2 Insiders Are Buying

The Dow Jones closed higher by more than 150 points on Thursday. When insiders purchase or sell shar

benzinga.com

HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target

HC Wainwright & Co. analyst Ed Arce reiterates Galectin Therapeutics (NASDAQ:GALT) with a Buy